title: Evolving standards of care for resected pancreatic cancer.
abstract: Pancreatic cancer is a devastating illness, and surgical resection offers the only chance of a cure for patients with the disease. Relatively few patients have resectable disease at diagnosis, however, and the cancer frequently recurs even after complete surgical resection. This review discusses clinical trials in which adjuvant therapy with chemotherapy or chemoradiation has prolonged survival in patients following surgery. It also highlights new data from the ESPAC-4 and JASPAC 01 studies that may change the current treatment paradigm for adjuvant therapy. The ESPAC-4 results support the use of adjuvant gemcitabine plus capecitabine in preference to the previous standard of gemcitabine alone, demonstrating that in this instance, more may be better. Finally, the review discusses ongoing trials and new approaches that aim to improve outcomes further for patients with resectable pancreatic cancer.
authors.affiliation: The Ruesch Center for the Cure of Gastrointestinal Cancers, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC.
authors.forename: Benjamin A
authors.initials: BA
authors.lastname: Weinberg
authors.affiliation: Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, Michigan.
authors.forename: Philip A
authors.initials: PA
authors.lastname: Philip
authors.affiliation: The Ruesch Center for the Cure of Gastrointestinal Cancers, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC.
authors.forename: Mohamed E
authors.initials: ME
authors.lastname: Salem
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D059186:Chemoradiotherapy, Adjuvant / Q000379:methods; D006801:Humans; D010180:Pancreatectomy; D010190:Pancreatic Neoplasms / Q000628:therapy*; D059039:Standard of Care / Q000639:trends*
chemical_list: D000970:Antineoplastic Agents